This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pendyala, L. Articles by Perez, R. Search for Related Content PubMed PubMed Citation Articles by Pendyala, L. Articles by Perez, R.

Intravenous Ifosfamide/Mesna Is Associated with Depletion of Plasma Thiols without Depletion of Leukocyte Glutathione¹

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263

Depletion of cellular glutathione (GSH) enhances the efficacy of many anticancer agents in preclinical systems. Limited published data showing depletion of GSH in vitro and in patients by ifosfamide and/or mesna provided the rationale for a Phase I trial. Ifosfamide and mesna were infused over 24 and 36 h, respectively, at equal daily doses; carboplatin was given after ifosfamide to a target plasma area under the curve of 4 mg·min·ml^-1. Plasma and peripheral WBC thiols were quantitated by high-performance liquid chromatography. The dose of ifosfamide was escalated from 2 to 8 g/m²; the maximum tolerated dose was 6 g/m². Significant depletion in plasma cysteine and homocysteine, precursors for GSH synthesis, was observed (maximum, 95% to >99% at 8 g/m²). Plasma mesna and cysteine/homocysteine levels were inversely correlated; nadir levels of cysteine/homocysteine were maintained for several hours after ifosfamide infusion had stopped and while mesna infusion was continuing. In vitro coincubation experiments confirmed that mesna reduces these thiols from disulfides to sulfhydryls, which are readily cleared, as evidenced by the significantly increased rate of excretion of cysteine in urine. In contrast, ifosfamide/mesna treatment caused a moderate depletion of plasma GSH in only 60% of the patients, with a nadir at 24 h and recovery immediately after the end of ifosfamide infusion. The GSH depletion in these patients was not dose related. The profile of GSH recovery in plasma after ifosfamide and the fact that mesna could not reduce GSH disulfides in vitro suggest that the observed GSH depletion in plasma in 60% of the patients may be related to direct reactions of GSH with ifosfamide metabolites and/or mesna. Our results indicate that mesna is a modulator of GSH precursors and that a prolonged infusion of mesna may be required to achieve GSH precursor starvation and the consequent GSH depletion in cells.

This article has been cited by other articles:

				B. L. Urquhart, D. J. Freeman, M. J. Cutler, R. Mainra, J. D. Spence, and A. A. House Mesna for Treatment of Hyperhomocysteinemia in Hemodialysis Patients: A Placebo-Controlled, Double-Blind, Randomized Trial Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1041 - 1047. [Abstract] [Full Text] [PDF]

				B. L. Urquhart, D. J. Freeman, J. D. Spence, and A. A. House Mesna as a Nonvitamin Intervention to Lower Plasma Total Homocysteine Concentration: Implications for Assessment of the Homocysteine Theory of Atherosclerosis J. Clin. Pharmacol., August 1, 2007; 47(8): 991 - 997. [Abstract] [Full Text] [PDF]

				P. F. Smith, B. M. Booker, P. Creaven, R. Perez, and L. Pendyala Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion J. Clin. Pharmacol., December 1, 2003; 43(12): 1324 - 1328. [Abstract] [Full Text] [PDF]

				M. C. Kuppner, A. Scharner, V. Milani, C. von Hesler, K. E. Tschop, O. Heinz, and R. D. Issels Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion Blood, November 15, 2003; 102(10): 3668 - 3674. [Abstract] [Full Text] [PDF]

				A.-K. Souid, R. C. Fahey, M. K. Aktas, O. A. Sayin, S. Karjoo, G. L. Newton, P. D. Sadowitz, R. L. Dubowy, and M. L. Bernstein Blood Thiols Following Amifostine and Mesna Infusions, a Pediatric Oncology Group Study Drug Metab. Dispos., November 1, 2001; 29(11): 1460 - 1466. [Abstract] [Full Text] [PDF]

				L. Pendyala, G. Schwartz, W. Bolanowska-Higdon, S. Hitt, J. Zdanowicz, M. Murphy, D. Lawrence, and P. J. Creaven Phase I/Pharmacodynamic Study of N-Acetylcysteine/Oltipraz in Smokers: Early Termination Due to Excessive Toxicity Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 269 - 272. [Abstract] [Full Text]